'None of the UK's coronavirus antibody tests are good enough to use'

Britain’s testing fiasco deepens as senior official admits NONE of the antibody kits ordered by the government from China are good enough to use

  • Government has reportedly ordered over a million tests that are no good 
  • Antibody tests, which show who has already had the virus, are vital for the UK 
  • But England testing chief says they aren’t sensitive enough for mildly ill patients
  • Officials are now working with manufacturers to help them improve products 

The UK’s chief of coronavirus testing has revealed that none of the antibody kits bought by the Government are good enough to use.

Professor John Newton, director of health improvement at Public Health England, said the tests were not accurate enough on people who had only had mild illnesses.

The tests, which reveal whether someone has already recovered from the disease, are considered to be crucial to ending Britain’s nationwide lockdown. 

Once in use they will give authorities a clear picture of how many people have caught the virus already and shaken it off. 

Currently, statistical guesswork is the only way of working out how many people might already be immune. Estimates suggest up to five million people could have been infected to date.

Professor Newton’s comments come after one expert in New York said people who catch the virus but don’t get seriously ill appear not to be making many antibodies, making it hard to test them. For this reason, he suggested, even good tests might only be 50-60 per cent accurate. 

A Government adviser in the UK added that other countries have had to send back failed tests – Spain had to return 640,000 that didn’t work – and said that devices he has been testing keep returning false negative and false positive results.

Professor John Newton, chief of COVID-19 testing for Public Health England, said none of the tests examined so far were accurate enough to roll out across the UK

Officials have reportedly bought test kits from the Chinese companies Wondo and Alltest but found that they are not accurate enough for official use

Professor Newton told The Times that the antibody tests bought by the Government so far were ‘not good enough to be worth rolling out’.

Health Secretary Matt Hancock last week claimed that 3.5million of the tests had been bought but admitted officials hadn’t proved they were any good.  

The Department of Health later rowed back and said it hadn’t actually bought the tests yet, just put an agreement in place to do so if they were up to scratch. 

In a statement the Department said it had ‘secured small numbers with potential to get much larger orders,’ The Telegraph reported.

An antibody test is one which tests whether someone’s immune system is equipped to fight a specific disease or infection.

When someone gets infected with a virus their immune system must work out how to fight it off and produce substances called antibodies.

These are extremely specific and are usually only able to tackle one strain of one virus. They are produced in a way which makes them able to latch onto that specific virus and destroy it.

For example, if someone catches COVID-19, they will develop COVID-19 antibodies for their body to use to fight it off.

The body then stores versions of these antibodies in the immune system so that if it comes into contact with that same virus again it will be able to fight it off straight away and probably avoid someone feeling any symptoms at all.

To test for these antibodies, medics or scientists can take a fluid sample from someone – usually blood – and mix it with part of the virus to see if there is a reaction between the two.

If there is a reaction, it means someone has the antibodies and their body knows how to fight off the infection – they are immune. If there is no reaction it means they have not had it yet.

And officials said they were working with at least nine manufacturers to try and get the project off the ground.

It is not clear what the threshold is for UK approval – one Chinese manufacturer believed to have supplied the Government claims its test is 98.6 per cent accurate.

PHE’s Professor Newton, however, said Government scientists were now having to go back to manufacturers and work with them to make the tests better.

Although tests appear accurate when used on people who were seriously ill with the coronavirus, they struggle to detect antibodies in people whose illnesses were mild.

Professor Newton said: ‘The test developed in China was validated against patients who were severely ill with a very large viral load, generating a large amount of antibodies,’ The Times reports.

‘We want to use the test in the context of a wider range of levels of infection including people who are quite mildly infected,’ he added. ‘So for our purposes, we need a test that performs better than some of these other tests.’    

Two of the tests ordered by the British Government come from Chinese firms called Wondfo and Alltest, according to ITV.

Wondfo claims on its website that its antibody test was the first one to be approved for official use in China, and it has been given emergency approval in the US and Australia. Its accuracy, however, is unclear.

Alltest, meanwhile, claims its tests are 98.6 per cent accurate at detecting long-term antibodies, which appear around two weeks after infection, but only 92.9 per cent accurate for antibodies produced between weeks two and four. 

Professor Newton’s comments follow claims by an expert at Columbia University in  New York, who said low levels of antibodies make long-term testing difficult. 

Dr David Ho said that people who don’t get seriously ill appear to take much longer to develop antibodies and therefore might test negative in early stages of recovery.

He told The Guardian: ‘The problem is after a couple of weeks, the detection rate remains at about 50 per cent to 60 per cent, especially in asymptomatic or mildly symptomatic cases. 

‘But this may not be a fault of the tests, because even using more sensitive methods in the lab we can see the antibody levels are quite low.’ 

More detailed long-term follow-up of patients will be necessary to see whether antibody levels in the blood increase over time, he added.

Source: Read Full Article